4.5 Article Proceedings Paper

IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 - Inflammatory bowel disease task force meeting

期刊

INFLAMMATORY BOWEL DISEASES
卷 17, 期 2, 页码 639-644

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/ibd.21409

关键词

-

资金

  1. IOIBD

向作者/读者索取更多资源

Every May 29th the World Gastroenterology Organization (WGO) celebrates World Digestive Health Day (WDHD) and initiates a worldwide public health campaign through its 110 national societies and 50,000 members. Each year focuses on a particular digestive disorder in order to increase general public awareness of prevention and therapy. 2010 is dedicated to inflammatory bowel disease (IBD). Upon this occasion a WGO IBD task force was compiled from leading international specialists and researchers. The task force also included members of the American Gastroenterological Association (AGA), International Organization for the Study of Inflammatory Diseases (IOIBD) and the European Crohn's and Colitis Organization (ECCO) of the United European Gastroenterology Federation (UEGF). The goal of the task force was to bring together IBD specialists from around the world to discuss the epidemiology, diagnosis, and management of IBD within different regions. This is a summary of the WGO task force meeting at the American Gastroenterological Association's (AGA) Digestive Disease Week, held in New Orleans, Louisiana, USA, May, 2010. The expert panel identified the most pressing issues in IBD worldwide: reliable epidemiological data, global collaboration in clinical and basic research, the approach to distinguishing intestinal tuberculosis from Crohn's disease, access to specialist care and access to the latest diagnostic and therapeutic strategies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and MMP10, MMP23 in inflammatory bowel disease: Cross-sectional study

Gabriela Fonseca-Camarillo, Janette Furuzawa-Carballeda, Braulio Martinez-Benitez, Rafael Barreto-Zuniga, Jesus K. Yamamoto-Furusho

Summary: In patients with active UC, EMMPRIN, MMP23 and MMP10 were upregulated, indicating their involvement in the inflammatory process.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2021)

Article Gastroenterology & Hepatology

Differential Cytokine Expression in the Duodenum and Rectum of Children with Non-Immunoglobulin E-Mediated Cow's Milk Protein Allergy

Erick M. Toro-Monjaraz, Gabriela Fonseca-Camarillo, Flora Zarate-Mondragon, Ericka Montijo-Barrios, Jose Cadena-Leon, David Avelar-Rodriguez, Jaime Ramirez-Mayans, Roberto Cervantes-Bustamante, Jesus K. Yamamoto-Furusho

Summary: In this study, it was observed that the immune response in CMPA appears to be mediated by a Th1, Th2, and Th17 cytokine profile, with the rectum being the main affected site.

DIGESTIVE DISEASES AND SCIENCES (2021)

Article Immunology

Expression of TOB/BTG family members in patients with inflammatory bowel disease

Gabriela Fonseca-Camarillo, Janette Furuzawa-Carballeda, Angel A. Priego-Ranero, Braulio Martinez-Benitez, Rafael Barreto-Zuniga, Jesus K. Yamamoto-Furusho

Summary: This study is the first to characterize the gene and protein expression of the TOB/BTG family in rectal and ileum tissues of IBD patients. Results showed decreased expression of TOB1 and BTG1 genes in colonic mucosa of UC patients, while overexpression of TOB2 and BTG2 genes in patients with UC in remission. High TOB2 gene expression was associated with histological remission.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2021)

Article Gastroenterology & Hepatology

Gene expression profiling of inflammatory cytokines in esophageal biopsies of different phenotypes of gastroesophageal reflux disease: a cross-sectional study

Monica R. Zavala-Solares, Gabriela Fonseca-Camarillo, Miguel Valdovinos, Julio Granados, Guido Grajales-Figueroa, Luis Zamora-Nava, Nancy Aguilar-Olivos, Luis R. Valdovinos-Garcia, Jesus K. Yamamoto-Furusho

Summary: This study found differential expression of inflammatory mediators in the esophageal mucosa of patients with different GERD endoscopic phenotypes. IL-1B and TNF-alpha could be useful for differentially diagnosing AAE and NAE in the non-erosive phenotype using endoscopic biopsies.

BMC GASTROENTEROLOGY (2021)

Article Immunology

Intestinal production of secreted protein acidic and rich in cysteine (SPARC) in patients with ulcerative colitis

Gabriela Fonseca-Camarillo, Janette Furuzawa-Carballeda, Natalia Razo-Lopez, Rafael Barreto-Zuniga, Braulio Martinez-Benitez, Jesus K. Yamamoto-Furusho

Summary: The study showed an increase in gene and protein expression of SPARC in patients with active UC, with significant correlation to histological activity. The results suggest that SPARC could be a marker of intestinal inflammation in UC.

IMMUNOBIOLOGY (2021)

Article Gastroenterology & Hepatology

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease

Bruce E. Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, Peter D. R. Higgins, Monika Fischer, Vipul Jairath, Fumihito Hirai, Geert D'Haens, Ruth M. Belin, Debra Miller, Elisa Gomez-Valderas, April N. Naegeli, Jay L. Tuttle, Paul F. Pollack, William J. Sandborn

Summary: Mirikizumab demonstrates efficacy and safety in patients with moderate-to-severe Crohn's disease. Significant endoscopic response is observed in the Mirikizumab groups compared to the placebo group at Week 12 and is sustained through Week 52. The frequency of adverse events is similar between Mirikizumab and placebo groups.

GASTROENTEROLOGY (2022)

Article Gastroenterology & Hepatology

Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis

William J. Sandborn, Laurent Peyrin-Biroulet, Daniel Quirk, Wenjin Wang, Chudy Nduaka, Arnab Mukherjee, Chinyu Su, Bruce E. Sands

Summary: In patients with ulcerative colitis who did not respond to initial treatment with tofacitinib, extended induction therapy (16 weeks) with 10 mg twice daily led to more than half of the patients (52.2%) achieving clinical response. Most delayed responders who continued to receive tofacitinib therapy were in remission at Month 36.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Review Gastroenterology & Hepatology

IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

Bram Verstockt, Azucena Salas, Bruce E. Sands, Clara Abraham, Haim Leibovitzh, Markus Neurath, Niels Vande Casteele

Summary: IL-12 and IL-23 play a crucial role in intestinal homeostasis and inflammation, and are implicated in the pathogenesis of inflammatory bowel disease. Monoclonal antibodies targeting IL-12 and/or IL-23 have been developed for the treatment of Crohn's disease and ulcerative colitis. This Review summarizes the biological characteristics of IL-12 and IL-23, discusses their role in intestinal homeostasis and inflammation, and highlights the development of drugs targeting IL-12 and/or IL-23.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)

Article Immunology

Differential expression of TOB/BTG family members in patients with plaque psoriasis: cross-sectional study

Carlos A. Barrera-Ochoa, Gabriela Fonseca-Camarillo, Maria Elisa Vega-Memije, Janette Furuzawa-Carballeda, Karen Uriarte-Ruiz, Dheni Aide Fernandez-Camargo, Jesus K. Yamamoto-Furusho

Summary: This study is the first to report the expression of TOB/BTG family genes and proteins in skin tissues from patients with plaque psoriasis. The mRNA levels and protein expression of TOB/BTG family were significantly decreased in psoriatic skin tissue compared to non-inflammatory control skin tissue. The expression of TOB1/2, BTG1,2, and BTG4/CD16 double-positive cells was found to be higher in normal control skin tissues and much lower in patients with plaque psoriasis, especially in moderate-severe patients.

IMMUNOLOGIC RESEARCH (2023)

Article Gastroenterology & Hepatology

Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD

Sophie Vieujean, James O. Lindsay, Ferdinando D'Amico, Vineet Ahuja, Mark S. Silverberg, Ajit Sood, Jesus K. Yamamoto-Furusho, Masakazu Nagahori, Mamoru Watanabe, Ioannis E. Koutroubakis, Kalliopi Foteinogiannopoulou, Irit Avni Biron, Alissa Walsh, An Outtier, Rie Louise Moller Nordestgaard, Maria T. Abreu, Marla Dubinsky, Corey Siegel, Edouard Louis, Iris Dotan, Walter Reinisch, Silvio Danese, David T. Rubin, Laurent Peyrin-Biroulet

Summary: This study analyzes the reasons for non-enrollment of IBD patients in RCTs and finds that patients are lost at each step, with eligibility criteria, the risk of placebo assignment, and insufficient disease activity being the main barriers.

JOURNAL OF CROHNS & COLITIS (2023)

Article Immunology

Increased synthesis and intestinal expression of IL-39 in patients with inflammatory bowel disease

Gabriela Fonseca-Camarillo, Janette Furuzawa-Carballeda, Rafael Barreto-Zuniga, Braulio Martinez-Benitez, Jesus K. Yamamoto-Furusho

Summary: This study identified increased expression of IL-39 in patients with inflammatory bowel disease, suggesting its potential role in regulating inflammation.

IMMUNOLOGIC RESEARCH (2023)

Meeting Abstract Gastroenterology & Hepatology

THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE

Amanda M. Johnson, Maria Barsky, Waseem Ahmed, Samantha Zullow, Jonathan S. Galati, Vipul Jairath, Neeraj Narula, Farhad Peerani, Benjamin H. Click, Elliot Coburn, Thucnhi T. Dang, Stephanie Gold, Manasi Agrawal, Rajat Garg, Manik Aggarwal, Danah Mohammad, Brendan P. Halloran, Gursimran Kochhar, Hannah Todorowski, Nabeeha Mohy-Ud-Din, James L. Izanec, Amanda M. Teeple, Christopher Gasink, Erik Muser, Zhijie Ding, Arun Swaminath, Komal Lakhani, Daniel Hogan, Samit Datta, Ryan C. Ungaro, Siddharth Singh, Brigid Boland, Matthew Bohm, Monika Fischer, Sagi Sashi, Anita Afzali, Thomas Ullman, Garrett Lawlor, Daniel C. Baumgart, Shannon Chang, David Hudesman, Dana J. Lukin, Ellen J. Scherl, Jean Frederic Colombel, Bruce E. Sands, Corey A. Siegel, Miguel D. Regueiro, William J. Sandborn, David H. Bruining, Sunanda V. Kane, Edward V. Loftus, Parambir Dulai

GASTROENTEROLOGY (2021)

Meeting Abstract Gastroenterology & Hepatology

SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB

Stephanie Gold, Manasi Agrawal, Vipul Jairath, Jonathan S. Galati, Elliot Coburn, Benjamin H. Click, Farhad Peerani, Neeraj Narula, Samantha Zullow, Waseem Ahmed, Maria Barsky, Amanda M. Johnson, Thucnhi T. Dang, Rajat Garg, Manik Aggarwal, Danah Mohammad, Brendan P. Halloran, Gursimran Kochhar, Hannah Todorowski, Nabeeha Mohy-Ud-Din, James L. Izanec, Amanda M. Teeple, Christopher Gasink, Erik Muser, Zhijie Ding, Arun Swaminath, Komal Lakhani, Daniel Hogan, Samit Datta, Siddharth Singh, Brigid Boland, Matthew Bohm, Monika Fischer, Sagi Sashi, David H. Bruining, Sunanda V. Kane, Edward V. Loftus, Anita Afzali, Thomas Ullman, Garrett Lawlor, Daniel C. Baumgart, Shannon Chang, David Hudesman, Dana J. Lukin, William J. Sandborn, Ellen J. Scherl, Corey A. Siegel, Miguel D. Regueiro, Jean Frederic Colombel, Bruce E. Sands, Parambir Dulai, Ryan C. Ungaro

GASTROENTEROLOGY (2021)

Meeting Abstract Gastroenterology & Hepatology

PREGNANCY OUTCOMES IN WOMEN EXPOSED TO USTEKINUMAB IN THE CROHN'S DISEASE AND ULCERATIVE COLITIS CLINICAL TRIALS

Bincy P. Abraham, Elyssa Ott, Christopher Busse, Conor J. Murphy, Lindsay Miller, Daniel C. Baumgart, Ellen J. Scherl, Christopher Gasink

GASTROENTEROLOGY (2021)

Article Gastroenterology & Hepatology

Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial

Bhairavi Balram, Harshad Joshi, Karen Wong, Karen I. Kroeker, Levinus A. Dieleman, Brendan P. Halloran, Daniel C. Baumgart, Farhad Peerani

Summary: This study found that continuing 5-ASA therapy in ulcerative colitis patients escalated to infliximab did not provide additional benefit in controlling inflammation, and was not associated with increased likelihood of achieving clinical and endoscopic remission.

DIGESTIVE DISEASES AND SCIENCES (2021)

暂无数据